VERICEL CORPORATION Total Liabilities and Equity
VERICEL CORPORATION (VCEL) had Total Liabilities and Equity of $502.87 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-30
- 2026-06-30: Liabilities and Equity $502.87M.
- 2026-03-31: Liabilities and Equity $485.63M.
- 2025-12-31: Liabilities and Equity $487.97M.
- 2025-09-30: Liabilities and Equity $453.27M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $502.87M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $485.63M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $487.97M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $453.27M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $435.61M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $424.59M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $432.72M 10-K · filed 2026-02-26 |
| 2024-09-30 | $390.40M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $376.84M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $356.66M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $353.66M 10-K · filed 2025-02-27 |
| 2023-09-30 | $318.13M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $310.71M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $265.10M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $273.00M 10-K · filed 2024-02-29 |
| 2022-09-30 | $248.02M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $244.81M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $240.29M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $243.71M 10-K · filed 2023-02-23 |
| 2021-09-30 | $224.14M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $221.94M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $211.46M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $205.61M 10-K · filed 2022-02-24 |
| 2020-09-30 | $157.50M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $146.69M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $150.26M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $153.24M 10-K · filed 2021-02-24 |
| 2019-09-30 | $137.53M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $125.83M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $141.23M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $118.69M 10-K · filed 2020-02-25 |
| 2018-09-30 | $124.46M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $122.19M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $52.41M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $54.58M 10-K · filed 2019-02-26 |
| 2017-09-30 | $40.28M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $36.53M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $40.59M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $48.60M 10-K · filed 2018-03-05 |
| 2016-09-30 | $28.02M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $29.43M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $33.06M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $34.31M 10-K · filed 2017-03-13 |
| 2015-09-30 | $35.82M 10-Q · filed 2015-11-13 |
| 2015-06-30 | $41.22M 10-Q · filed 2015-08-12 |
| 2015-03-31 | $44.49M 10-Q · filed 2015-05-14 |
| 2014-12-31 | $47.58M 10-K · filed 2016-03-14 |
| 2014-09-30 | $50.38M 10-Q · filed 2014-11-13 |
| 2014-06-30 | $19.84M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $9.88M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $9.21M 10-K · filed 2015-03-25 |
| 2013-09-30 | $12.20M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $5.68M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $10.58M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $15.18M 10-K · filed 2014-03-13 |
| 2012-09-30 | $22.71M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $30.44M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $38.66M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $7.74M 10-K · filed 2013-03-18 |
| 2011-09-30 | $14.07M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $20.30M 10-Q · filed 2011-08-15 |
| 2010-12-31 | $32.83M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |